Cargando…

Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazharuddin, Anam A., Whyte, Andrew T., Gombos, Dan S., Patel, Nimisha, Razmandi, Azadeh, Chaudhry, Amina L., Al-Zubidi, Nagham S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Innovative Healthcare Institute 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714419/ https://www.ncbi.nlm.nih.gov/pubmed/36483585 http://dx.doi.org/10.36401/JIPO-22-14

Ejemplares similares

Ocular Toxicity Profile of Targeted Cancer Therapy (TCT) at a US Tertiary Cancer Center
por: Ameri, Moe, et al.
Publicado: (2023)

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
por: Lu, Rebecca, et al.
Publicado: (2023)

Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab
por: Khimani, Karima, et al.
Publicado: (2022)

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions
por: Fu, Chen, et al.
Publicado: (2017)

Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions
por: Fu, Chen, et al.
Publicado: (2019)

Systemic corticosteroids in nonarteritic ischemic optic neuropathy
por: Al-Zubidi, Nagham, et al.
Publicado: (2014)

Neuro-ophthalmology as a career
por: Spitze, Arielle, et al.
Publicado: (2014)

Controversies: Optic nerve sheath fenestration versus shunt placement for the treatment of idiopathic intracranial hypertension
por: Spitze, Arielle, et al.
Publicado: (2014)

Terror-Related Ocular Trauma in Patients Presenting to a Tertiary Eye Center in the Middle East
por: Al-Amry, Mohammad, et al.
Publicado: (2022)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
por: Liu, Xiaowei, et al.
Publicado: (2020)

An Uncharacteristic Presentation of Evans Syndrome Following Treatment With Dupilumab
por: Rutherford, Megan, et al.
Publicado: (2021)

Mode of Managing Ocular Inflammations
por: Whyte, D.
Publicado: (1802)

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
por: Huang, Qian, et al.
Publicado: (2020)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Ocular Inflammation Induced by Immune Checkpoint Inhibitors
por: Chaudot, Florence, et al.
Publicado: (2022)

Oxaliplatin-Related Ocular Toxicity
por: Mesquida, Marina, et al.
Publicado: (2010)

Ocular Candidiasis in Patients with Candidemia at a Large Tertiary Care Center
por: Lee, Bonny, et al.
Publicado: (2017)

Bacteriophages targeting Enterococcus faecalis strains - a potential new root canal therapy
por: Al Zubidi, Mohammed
Publicado: (2017)

New Highlights of Resveratrol: A Review of Properties against Ocular Diseases
por: Delmas, Dominique, et al.
Publicado: (2021)

Presentation and Management of Orbito-Ocular Malignancies in a Tertiary Institution in Southwest Nigeria
por: Alabi, Adewumi Olabimpe, et al.
Publicado: (2023)

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman
por: Salman, Bushra, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma
por: Brockwell, Natasha K., et al.
Publicado: (2020)

Ocular Comorbidities Contributing to Death in the US
por: Huang, Ryan S., et al.
Publicado: (2023)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

Ocular morbidity and co-morbidities in children attending a nodal district early intervention center in Uttar Pradesh
por: Masood, Anam, et al.
Publicado: (2023)

Ocular toxicity of Calotropis - missing links
por: Lakhtakia, Sujata, et al.
Publicado: (2010)

Ocular toxicity of systemic anticancer chemotherapy
por: Omoti, Afekhide Ernest, et al.
Publicado: (2006)

Ocular toxicity of authentic lunar dust
por: Meyers, Valerie E, et al.
Publicado: (2012)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

Nanoparticles in ocular applications and their potential toxicity
por: Yang, Cao, et al.
Publicado: (2022)

Study of Ocular Manifestations of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
por: Abrol, Arundha, et al.
Publicado: (2020)

Ocular manifestations in children with developmental delay at a tertiary center in South India
por: Hegde, Vidya, et al.
Publicado: (2021)

Ocular Neisseria gonorrhea in a patient on immune checkpoint inhibitors
por: Sopeyin, Anuoluwapo, et al.
Publicado: (2021)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Highlight report: Cell type selection for toxicity testing
por: Bolt, H. M.
Publicado: (2018)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
por: Noelle, Randolph J., et al.
Publicado: (2023)

Commentary: Squamous cell carcinoma of the esophagus: Another target for checkpoint inhibition
por: Whyte, Richard I.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ovu846tt0rf640qeqsp492oeb6